iibr-100
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Oct 28, 2020 (NCT04608305)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04990466 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2021 | Cromos Pharma, LLC, Israel Institute for Biological Research, NeuroRx, Inc., NRx Pharmaceuticals |
| NCT04608305 | Phase 1/Phase 2 (Phase 2) | Oct 28, 2020 | Israel Institute for Biological Research (IIBR) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cromos Pharma, LLC | For profit | 1 | 0 | 1 | 2021 |
| Israel Institute for Biological Research | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Israel Institute for Biological Research (IIBR) | Academic/Hospital | 1 | 1 | 1 | 2020 |
| NeuroRx, Inc. | For profit | 1 | 1 | 1 | 2021 |
| NRx Pharmaceuticals | For profit | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1